

Sheet 1 of 3

<b>SUBSTITUTE FORM PTO-1449 (MODIFIED)</b>  <b>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	<b>Attorney Docket No.</b>	50125/111001
	<b>Serial No.</b>	10/577,751
	<b>Applicant</b>	Dugas et al.
	<b>Filing Date</b>	January 22, 2007
	<b>Group</b>	1751
	<b>IDS Filed</b>	January 24, 2008

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
	5,210,015	05/11/1993	Gelfand et al.
	5,445,934	08/29/1995	Fodor et al.
	5,487,972	01/30/1996	Gelfand et al.
	5,700,637	12/23/1997	Southern
	5,744,305	04/28/1998	Fodor et al.
	5,804,375	09/08/1998	Gelfand et al.
	5,945,334	08/31/1999	Besemer et al.
	6,174,670	01/16/2001	Wittwer et al.
	6,785,101	08/31/04	Webb et al.
	2003/011943	01/16/03	Webb et al.

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
	EP 0373203	08/31/1994	EPO	
	EP 0619321	01/07/1999	EPO	
	EP 1043676	10/11/2000	EPO	
	EP 0543942	01/24/2001	EPO	
	WO 92/02638	02/20/1992	WIPO	
	WO 03/039443	05/15/2003	WIPO	
	WO 03/083140	10/09/2003	WIPO	

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50125/111001
	Serial No.	10/577,751
	Applicant	Dugas et al.
	Filing Date	January 22, 2007
	Group	1751
	IDS Filed	January 24, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Alizadeh et al., "The Lymphochip: A Specialized cDNA Microarray for the Genomic-scale Analysis of Gene Expression in Normal and Malignant Lymphocytes," <i>Cold Spring Harb. Symp. Quant. Biol.</i> 64:71-78 (1999).
	Andersen and Gill, "Cox's Regression Model for Counting Processes: A Large Sample Study," <i>Ann. Stat.</i> 10:1100-1120 (1982).
	Boissel et al., "Prognostic Significance of FLT3 Internal Tandem Repeat in Patients with De Novo Acute Myeloid Leukemia Treated with Reinforced Courses of Chemotherapy," <i>Leukemia</i> 16:1699-1704 (2002).
	Brown et al., "Knowledge-based Analysis of Microarray Gene Expression Data by Using Support Vector Machines," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 97:262-267 (2000).
	Byrd et al., "Pre-treatment Cytogenetics Predict Outcome in Patients with Acute Myeloid Leukemia," <i>Meet. Abstr.</i> p1-3. 43 <sup>rd</sup> Annual Meeting of the American Society of Hematology, Part 1; Orlando, Florida, USA; December 07-11, 2001.
	Dugas et al., "A Comprehensive Leukemia Database: Integration of Cytogenetics, Molecular Genetics and Microarray Data with Clinical Information, Cytomorphology and Immunophenotyping," <i>Leukemia</i> 15:1805-1810 (2001).
	Dugas et al., "Impact of Integrating Clinical and Genetic Information," <i>In Silico Biol.</i> 2:383-391 (2002).
	Furey et al., "Support Vector Machines Classification and Validation of Cancer Tissue Samples Using Microarray Expression Data," <i>Bioinformatics</i> 16:906-914 (2000).
	Golub et al., "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring," <i>Science</i> 286:531-537 (1999).
	Harlow and Lane, "Antibodies: A laboratory manual," <i>Cold Spring Harbor Press Inc.</i> (1988).
	<a href="http://www.affymetrix.com">http://www.affymetrix.com</a>
	<a href="http://www.csie.ntu.edu.tw/~cjlin/libsvm">http://www.csie.ntu.edu.tw/~cjlin/libsvm</a>
	<a href="http://www.ncbi.nlm.nih.gov/geo">http://www.ncbi.nlm.nih.gov/geo</a>
	<a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL96">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL96</a> (2002)
	Kamada et al., "Crystal Structure of Negative Cofactor 2 Recognizing the TBP-DNA Transcription Complex," <i>Cell</i> 106:71-81 (2001).
	Köhler and Milstein, "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," <i>Nature</i> 256:495-497 (1975).
	Klaus et al., "Trisomies are Frequently Observed in AML," <i>Meet. Abstr.</i> p1-2. 44 <sup>th</sup> Annual Meeting of the American Society of Hematology; Philadelphia, PA, USA; December 06-10, 2002.
EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.  Serial No.  Applicant  Filing Date  Group  IDS Filed	50125/111001  10/577,751  Dugas et al.  January 22, 2007  1751  January 24, 2008
--	--	---	--

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Kohlmann et al., "Molecular Characterization of Acute Leukemias by Use of Microarray Technology," <i>Genes Chromosomes Cancer</i> 37:396-405 (2003).
	Liu et al., "NetAffx: Affymetrix Probesets and Annotations," <i>Nucleic Acids Res.</i> 31:82-86 (2003).
	Sambrook et al., "Molecular Cloning: A Laboratory Manual," <i>Cold Press Harbor Laboratory Press Inc.</i> (1989).
	Schnittger et al., "Screening for MLL Tandem Duplication in 387 Unselected Patients with AML Identify a Prognostically Unfavorable Subset of AML," <i>Leukemia</i> 14:796-804 (2000).
	Schoch et al., "The Significance of Trisomy 8 in de Novo Acute Myeloid Leukemia: the Accompanying Chromosome Aberrations Determine the Prognosis," <i>Br. J. Haematol.</i> 99:1-2 (1997).
	Storey and Tibshirani, "Statistical Significance for Genomewide Studies," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 100:9440-9445 (2003).
	Vapnik, "Statistical Learning Theory" <i>Wiley-Interscience Publication</i> (1998).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	